Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2024 07:00 ET | Source: InspireMD, Inc.

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
March 06, 2024 07:00 ET | Source: InspireMD, Inc.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device...
February 28, 2024 07:00 ET | Source: InspireMD, Inc.

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™...
February 12, 2024 07:00 ET | Source: InspireMD, Inc.

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke,...
January 31, 2024 07:00 ET | Source: InspireMD, Inc.

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke,...
January 03, 2024 07:00 ET | Source: InspireMD, Inc.

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4)...
December 20, 2023 07:00 ET | Source: InspireMD, Inc.

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today...
November 27, 2023 07:00 ET | Source: InspireMD, Inc.

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

TEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
November 06, 2023 07:00 ET | Source: InspireMD, Inc.

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from...
November 02, 2023 08:00 ET | Source: InspireMD, Inc.

InspireMD to Participate in Upcoming November Investor Conferences

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right